Why H J, Meany B T, Richardson P J, Olsen E G, Bowles N E, Cunningham L, Freeke C A, Archard L C
Cardiac Department, King's College Hospital, Denmark Hill, London, UK.
Circulation. 1994 Jun;89(6):2582-9. doi: 10.1161/01.cir.89.6.2582.
Enteroviral RNA sequences have been demonstrated in the myocardium of patients with myocarditis or dilated cardiomyopathy from presentation to end-stage disease. The prognosis of heart muscle disease has not previously been evaluated in relation to the detection of enterovirus in myocardial biopsy tissue.
We studied 123 consecutive patients with heart muscle disease prospectively. Multiple endomyocardial biopsy samples taken from all patients during diagnostic cardiac catheterization were classified histologically and were examined for enteroviral RNA by use of an enterovirus group-specific hybridization probe. Three enterovirus-negative patients with cardiac amyloidosis were excluded from subsequent analysis. Enteroviral RNA sequences were detectable in 41 (34%) of the remaining 120 patients (group A), while 79 (66%) had no virus detected (group B). The groups did not differ significantly in age, sex, symptomatic presentation, or hemodynamic characteristics; duration of symptoms was significantly shorter in group A (7.8 +/- 9.6 versus 14.9 +/- 19.0 months, P < .05). At follow-up (mean, 25 months; range, 11 to 50 months), patients from group A had an increased mortality compared with those in group B (25% versus 4%, respectively; P = .02). Mortality was also statistically greater in patients with symptomatic cardiac failure (P = .02), those with elevated left ventricular end-diastolic pressures (P = .03), and those in New York Heart Association functional classes III and IV (P = .05). Multivariate regression analysis, however, showed that only the presence of enterovirus RNA and symptomatic heart failure were of independent prognostic value.
These data demonstrate that the detection of enterovirus RNA in the myocardium of patients with heart muscle disease at the time of initial investigation is associated with an adverse prognosis and that the presence of enterovirus RNA is an independent predictor of clinical outcome.
从心肌炎或扩张型心肌病患者发病至疾病终末期,心肌中均已检测到肠道病毒RNA序列。此前尚未就心肌活检组织中肠道病毒的检测情况对心肌疾病的预后进行评估。
我们对123例连续性心肌疾病患者进行了前瞻性研究。在诊断性心导管检查期间,从所有患者采集的多个心内膜心肌活检样本进行了组织学分类,并使用肠道病毒组特异性杂交探针检测肠道病毒RNA。3例肠道病毒阴性的心脏淀粉样变性患者被排除在后续分析之外。其余120例患者中,41例(34%)可检测到肠道病毒RNA序列(A组),79例(66%)未检测到病毒(B组)。两组在年龄、性别、症状表现或血流动力学特征方面无显著差异;A组症状持续时间明显短于B组(分别为7.8±9.6个月和14.9±19.0个月,P<0.05)。随访(平均25个月;范围11至50个月)时,A组患者的死亡率高于B组(分别为25%和4%;P = 0.02)。有症状性心力衰竭的患者(P = 0.02)、左心室舒张末期压力升高的患者(P = 0.03)以及纽约心脏协会功能分级为III级和IV级的患者(P = 0.05),其死亡率在统计学上也更高。然而,多因素回归分析显示,只有肠道病毒RNA的存在和有症状性心力衰竭具有独立的预后价值。
这些数据表明,在初始研究时,心肌疾病患者心肌中肠道病毒RNA的检测与不良预后相关,且肠道病毒RNA的存在是临床结局的独立预测因素。